Key result
High glycoprotein IIb-IIIa content correlated with increased ADP-induced platelet aggregation (r=0.315 to 0.591) and decreased efficacy of aggregation inhibition by aspirin.
Why the study?
Does GP IIb-IIIa content influence platelet aggregation activity and the efficacy of aspirin in healthy donors?
Observational (n=35)
Does GP IIb-IIIa content influence platelet aggregation activity and the efficacy of aspirin in healthy donors?
Higher GP IIb-IIIa receptor content on platelets is associated with increased platelet aggregation and reduced efficacy of aspirin, independent of GP IIIa Leu33Pro polymorphism.
GP IIb-IIIa content should not guide aspirin use in healthy donors; leaves open its role in modulating response among cardiovascular patients.
Effects of fibrinogen receptor, glycoprotein (GP) IIb-IIIa (alphaII/(beta3-integrin) content, GP IIIa genetic polymorphism (substitution Leu33Pro) and fibrinogen concentration in blood plasma on platelet aggregation activity were studied in a group of healthy volunteers. The GP IIb-IIIa content on platelet surface in 35 tested donors varied (40-71) x 10(3) per platelet. Repeated measurements revealed that the GP IIb-IIIa content coefficient of variation was 9.5%, and deviations from mean levels did not exceed 20%. The level and rate of platelet aggregation induced by ADP (1.25-20 M) correlated with GP IIb-IIIa number (r from 0.315 to 0.591) and were higher in a group of donors with high in comparison with low GP IIb-IIIa content (> 60 and (40-50) x 10(3) per platelet respectively). Aspirin, the inhibitor of thromboxane A2 synthesis, partially suppressed ADP-induced platelet aggregation. The level of residual aggregation in the presence of aspirin also correlated with GP IIb-IIIa content and increased in subjects with high receptor content. Parameters of ADP-induced aggregation did not differ in donors with GP IIIa Pro33(-) (Leu33Leu33, n = 20) and Pro33(+) (Leu33Pro33, n = 13, and Pro33Pro33, n = 2) genotype. GP IIb-IIIa content was also not affected by GP IIIa polymorphism. No significant correlations were found between the level and rate of platelet aggregation and fibrinogen concentration in blood plasma. The data obtained indicate that effects of GP IIb-IIIa variations in content on platelet aggregation are higher than GP IIIa Leu33Pro polymorphism and variations of fibrinogen concentration. High GP IIb-IIIa content is associated with increased platelet aggregation activity and decreased efficacy of aggregation inhibition by aspirin.
No takes yet. Share an insight, caveat, or question.
Хаспекова et al. (2009) conducted an observational in Healthy volunteers (n=35). High glycoprotein IIb-IIIa content vs. Low glycoprotein IIb-IIIa content was evaluated on Platelet aggregation activity induced by ADP. High glycoprotein IIb-IIIa content correlated with increased ADP-induced platelet aggregation (r=0.315 to 0.591) and decreased efficacy of aggregation inhibition by aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: